Economic Atlas
Data may be delayed — last successful sync 2026-09-26 (18 days ago). Figures reflect the most recent completed ingest.
Companies/Cannara Biotech Inc.
Company profile

Cannara Biotech Inc.

OTC: LOVFF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Montréal, QCReports USD
#378 of 1,417 Healthcare companies by revenue71st-percentile growth
EA Score
76B+
Revenue TTM
$85.4M
Rev growth YoY (TTM)
+16.9%
Net income (FY)
$9.4M
Employees
452
as of 2026-09-15
Market cap
$141.3M
as of 2026-09-15

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$76.8M107.3M CAD2025
Net income$9.4M13.1M CAD2025
Operating income$15.9M22.2M CAD2025
Total assets$122.7M168.6M CAD2025
Liabilities$48.3M66.4M CAD2025
Equity$74.4M102.2M CAD2025

Revenue trend

FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Cannara Biotech Inc.’s revenue?

Cannara Biotech Inc. booked $76.8M in FY2025 revenue, growing 28% year over year — faster than most Healthcare companies we track, at a 12.2% net margin.

Peers · Healthcare
Eton Pharmaceuticals, Inc.60CVitalhub Corp.77B+Sight Sciences, Inc.53DCytomX Therapeutics, Inc.63CInterpharm Holdings, Inc.——Lifecore Biomedical, Inc.66B
Key facts
CEOZohar Krivorot
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersMontréal, QC
ExchangeOTC: LOVFF
Employees452
IPO date2019-01-18
Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.